MedImmune presents new data showing burden of RSV disease
Tuesday, May 5, 2009 - 13:42
in Health & Medicine
BALTIMORE, MD, May 5, 2009 - MedImmune today announced results from a recent study it sponsored, performed by the Kaiser Permanente Division of Research in Oakland, CA, assessing risk factors for respiratory syncytial virus (RSV) infection requiring medical treatment in infants born at 33 weeks gestational age [GA] or later.